What is Alio?
Alio operates at the intersection of medical technology and data analytics, addressing the critical inefficiencies inherent in current remote patient monitoring systems. By replacing invasive and costly legacy tools with sophisticated, clinical-grade sensors, Alio provides a seamless user experience that significantly improves patient compliance. The platform distinguishes itself by aggregating complex physiological data into actionable insights, effectively bridging the gap between raw sensor output and clinical decision-making. While initially engineered for healthcare environments, the underlying technology possesses the versatility to serve a broad spectrum of industries requiring high-accuracy, non-invasive monitoring solutions.
How much funding has Alio raised?
Alio has raised a total of $49M across 3 funding rounds:
Series A
$11M
Series B
$20M
Series C
$18M
Series A (2018): $11M, investors not publicly disclosed
Series B (2021): $20M led by Zekavat Investment Group and Thomas Krebs
Series C (2022): $18M supported by Chase Field, Widjaja Family Investment Office, and LLC
Key Investors in Alio
Chase Field
An investment entity with a diverse portfolio, providing strategic backing to high-growth technology firms.
Widjaja Family Investment Office
A private investment office focused on long-term capital appreciation and supporting innovative healthcare ventures.
Zekavat Investment Group
A venture-focused group specializing in scaling early-to-mid-stage companies through targeted financial support and operational guidance.
What's next for Alio?
With the successful closure of its latest financing round, Alio is well-positioned to accelerate its product roadmap and expand its footprint within the enterprise healthcare sector. The strategic focus will likely shift toward scaling manufacturing capabilities and deepening the integration of its diagnostic platform into existing clinical workflows. By leveraging this capital, Alio aims to further refine its proprietary algorithms, ensuring that the actionable insights provided to clinicians remain at the forefront of medical innovation. As the demand for remote, high-accuracy health monitoring continues to rise, Alio's ability to deliver reliable, non-invasive data will be a key driver in its long-term market penetration and competitive differentiation.
See full Alio company page
